Table 3.
Univariate and Multivariate Analysis of the Prognostic Factors for PFS in All Patients
| Variable | Univariate | Multivariate | ||
|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | |
| Gender | 0.400 (0.134–1.196) | 0.101 | ||
| Male | ||||
| Female | ||||
| Age | 0.335 (0.813–3.671) | 0.155 | ||
| ≥65 | ||||
| <65 | ||||
| Child-Pugh | 0.740 (0.271–2.019) | 0.556 | ||
| A | ||||
| B | ||||
| ECOG-PS | 0.682 (0.306–1.520) | 0.350 | ||
| 0–1 | ||||
| 2 | ||||
| Platelet (×10^9/L) | 0.954 (0.216–4.213) | 0.951 | ||
| ≥100 | ||||
| <100 | ||||
| Total bilirubin (umol/L) | 0.909 (0.207–3.981) | 0.899 | ||
| ≥34 | ||||
| <34 | ||||
| Albumin (g/L) | 1.340 (0.451–3.988) | 0.598 | ||
| ≥35 | ||||
| <35 | ||||
| ALT (IU/L) | 0.204 (0.606–1.372) | 0.657 | ||
| ≥40 | ||||
| <40 | ||||
| AST (IU/L) | 0.989 (0.628–1.610) | 0.982 | ||
| ≥40 | ||||
| <40 | ||||
| ALBI grade (≥2 vs 1) | 0.894 (0.607–1.473) | 0.805 | ||
| ≥2 | ||||
| 1 | ||||
| AFP (ng/mL) | 1.316 (0.574–1.325) | 0.520 | ||
| ≥400 | ||||
| <400 | ||||
| Maximum tumor size (cm) | 0.940 (0.560–1.899) | 0.921 | ||
| ≥5 | ||||
| <5 | ||||
| Anti-PD-1 antibodies | 0.836 (0.256–1.632) | 0.687 | ||
| Sintilimab | ||||
| Tislelizumab | ||||
| Camrelizumab | ||||
| Tumor number | 0.340 (0.993–2.963) | 0.053 | ||
| Solitary | ||||
| Multiple | ||||
| Operation | 3.492 (1.164–10.475) | 0.026 | 3.492 (1.164–10.475) | 0.026 |
| Yes | ||||
| No | ||||
| Extrahepatic metastasis | 2.514 (0.554–11.411) | 0.332 | ||
| Yes | ||||
| No | ||||
Note: Bold values is to highlight the meaningful p-values.
Abbreviations: PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; ALT, alanine transaminase; AST, aspartate transaminase; ALBI, albumin-bilirubin; AFP, ɑ-fetoprotein; HBsAg, hepatitis B surface antigen.